Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
NCT ID: NCT03680365
Last Updated: 2019-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2018-09-20
2019-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DMD Voice: Qualitative Interviews With Patients and Caregivers
NCT06925269
The Burden of Access in Duchenne Muscular Dystrophy in the US
NCT03951675
Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)
NCT00468832
This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy
NCT01098708
Evaluation of Home Based Assessments on Participants With DMD
NCT05657938
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmed diagnosis of DMD with written proof of disease provided
3. Resident of the U.S.
4. Able to read, write and communicate in English
5. Able to grant informed consent
6. Willing to participate in a 45 minute telephone interview
7. Ability to view or receive a document from the interviewer before or during the interview (web browser, ability to receive a text, fax or document by mail)
11 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Engage Health Inc.
INDUSTRY
Hyman, Phelps, & McNamara, P.C.
UNKNOWN
Ryans Quest Inc.
UNKNOWN
Michaels Cause Inc.
UNKNOWN
Nationwide Children's Hospital
OTHER
Solid Biosciences Inc.
INDUSTRY
Santhera Pharmaceuticals
INDUSTRY
Italfarmaco
INDUSTRY
Catabasis Pharmaceuticals
INDUSTRY
Wave Life Sciences Ltd.
INDUSTRY
Sarepta Therapeutics, Inc.
INDUSTRY
Hoffmann-La Roche
INDUSTRY
Pfizer
INDUSTRY
Capricor Inc.
INDUSTRY
NS Pharma, Inc.
INDUSTRY
Jett Foundation, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine McSherry, R.N.
Role: PRINCIPAL_INVESTIGATOR
Jett Foundation, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Engage Health, Inc.
Eagan, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018 Mar;17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3.
Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018 Apr;17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3.
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR, Ward LM; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018 May;17(5):445-455. doi: 10.1016/S1474-4422(18)30026-7. Epub 2018 Feb 2.
Related Links
Access external resources that provide additional context or updates about the study.
Jett Foundation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Jett 0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.